Fig. 2From: A prospective phase-II trial of biweekly docetaxel plus androgen deprivation therapy in patients with previously-untreated metastatic castration-naïve prostate cancerKaplan-Meier curves for CRPC-free survival of chemotherapy-naïve prostate cancer patients (N = 42) treated with biweekly docetaxel plus androgen-deprivation therapy. CRPC: castration resistant prostate cancerBack to article page